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Abstract
Long-term exposure of the pancreatic L cells to free fatty acid (FFA) reportedly inhibits glucose-stimulated insulin
secretion. We here studied the impact of FFA on glucose and lipid metabolism in pancreatic L cells with special reference to
insulin secretion. Pancreatic L-cell line MIN6 was exposed to various concentrations of palmitate for 3 days. Glucose-
stimulated insulin secretion and insulin content were decreased corresponding to the concentration of the palmitate exposed.
Glycolytic flux and ATP synthesis was unchanged, but pyruvate-stimulated change in NAD(P)H concentration was
decreased. Pyruvate carboxylase was decreased at the protein level, which was restored by the removal of palmitate or the
inhibition of L-oxidation. Intracellular content of triglyceride and FFA were elevated, L-oxidation was increased, and de
novo lipogenesis from glucose was decreased. NADPH content and citrate output into the medium, which reflected pyruvate
malate shuttle flux, were decreased, but malic enzyme activity was unaffected. The malic enzyme inhibitor alone inhibited
insulin response to glucose. In conclusion, long-term exposure of FFA to L cells inhibits glucose-stimulated insulin secretion
via the decreased NADPH contents due to the inhibition of pyruvate carboxylase and malate pyruvate shuttle flux. ß 2002
Elsevier Science B.V. All rights reserved.
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1. Introduction
In diabetic patients, obesity aggravates hepatic
glucose overproduction and peripheral insulin resis-
tance leading to hyperglycemia [1]. Free fatty acid
(FFA) increases glucose output in cultured hepato-
cytes and decreases insulin sensitivity in myocytes [1^
3]. Visceral fat tissues release FFA into the portal
veins, which is considered to play a role in the etiol-
ogy of hepatic glucose overproduction [1].
FFA exhibits dual e¡ects on insulin secretion.
Acute exposure of L cells to FFA potentiates glu-
cose-stimulated insulin secretion [4], whereas long-
term treatment is known to inhibit it [5]. The latter
phenomenon is currently explained from the aspects
of insulin biosynthesis and glucose metabolism [6,7].
It is reported that the inhibition of the glucose-stimu-
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lated insulin secretion is associated with the de-
creased glucose oxidation and pyruvate dehydroge-
nase activity [7]. Controversially, increased basal glu-
cose usage and insulin secretion are also reported
with a lowered level of G-6-P and 50% reduction in
citrate synthase activity [8].
Cytosolic NADPH/NADP ratio increases in glu-
cose-stimulated islet cells [9]. Production of cytosolic
NADPH largely depends upon the malate pyruvate
shuttle rather than the pentose phosphate shuttle in
the islets [10]. Malate pyruvate shuttle £ux is regu-
lated by pyruvate carboxylase (PC) [11]. PC is abun-
dantly expressed in pancreatic L cells as well as in
liver and kidney [12]. In the islets of some diabetic
animals, PC protein is decreased and is normalized
by the insulin treatment [13]. These suggest that py-
ruvate carboxylase and pyruvate malate shuttle
contribute to the modulation of cytosolic pyridine
nucleotide content and glucose-stimulated insulin se-
cretion.
In the present study, we investigated the e¡ect of
FFA on L-cell glucose and lipid metabolism during
insulin secretion. By focusing on pyruvate carboxy-
lase and pyruvate malate shuttle activity, the long-
term metabolic e¡ect of FFA has been discussed with
reference to glucose insensitivity of L cells.
2. Materials and methods
2.1. Materials
Palmitic acid (sodium salt), bovine serum albumin
(fraction V) (BSA) were purchased from Sigma
Chemical Co. (St. Louis, MO). Dulbecco’s modi¢ed
Eagle medium (DMEM) and phosphate-bu¡ered sa-
line without calcium and magnesium (PBS(3)) were
from Nikken (Tokyo, Japan). Insulin, FFA, trigly-
ceride and lactate were assayed using commercially
available kits, Grazyme insulin assay kit Wako
(Wako Chemical, Osaka, Japan), NEFA-C test
Wako (Wako Chemical), Lipidos Ace (Toyobo, To-
kyo, Japan), and Lactate Assay kit (Kyowa Medix,
Tokyo, Japan) to measure even the smallest amount
of material. Assay protocols followed the manufac-
turers’ recommendations. Rat insulin was kindly sup-
plied by Eli Lilly Co. (Indianapolis, IN, USA).
[2-3H]glucose, [6-3H]glucose, [2-3H]glycerol and
[U-13C]glucose were from Pharmacia Amersham Bi-
otech (Buckinghamshire, UK). MIN6 cells were
grown in DMEM (25 mM glucose) equilibrated
with 5% CO2 and 95% air at 37‡C as described [14].
2.2. Measurement of glucose metabolism
Cells were incubated with HEPES Krebs Ringer
bicarbonate (HKRB) bu¡er (119 mM NaCl, 4.74
mM KCl, 2.54 mM CaCl2, 1.19 mM KH2PO4, 25
mM NaHCO3, 10 mM HEPES, pH 7.4) containing
0.2% bovine serum albumin (BSA), 5.5 mM glucose
and 20 Ci/ml [2-3H]glucose for glucose phosphoryla-
tion, or [6-3H]glucose for glucose usage for 2 h. After
incubation in the media including the tritiated glu-
cose for 2 h, the media were collected. To separate
the tritiated water from radioactive glucose, a 20-ml
£ask containing 1 ml of distilled water was sealed
with stopper. Samples of 300 l in the cup was kept
in the £ask at 37‡C for 24 h to allow 3H2O in the
samples to equilibrate with the water [15]. The recov-
ery from known amounts of 3H2O water was aver-
aged at 50^60%. The radioactivity in the water was
measured by a liquid scintillation counter. Glycerol
phosphate shuttle activity was determined at 5.5 and
15 mM glucose to measure 3H2O production from
[3H]glycerol [16]. Lactate output was measured by
using a Lactate Determina kit (Toyobo). Brie£y,
Cells were pre-incubated for 80 min in glucose-free
HKRB bu¡er and incubated in HKRB bu¡er con-
taining 5.5 and 15 mM glucose, respectively, each for
20 min. After the incubated media were collected,
lactate concentrations in the collected media were
measured according to the manufacturer’s protocol.
Citrate output was measured as reported by Prentski
et al. [17]. Brie£y, cells were preincubated for 20 min
in glucose-free HKRB bu¡er and incubated in 1 ml
HKRB bu¡er containing 5.5 mM and 15 mM glu-
cose, respectively, for 30 min. The media were col-
lected and added in 1 ml 10% TCA. After centrifu-
gation of precipitated proteins, cell extracts were
brought to pH 5^6 by successive ether extractions.
Samples were lyophilized and stored at 380‡C. Cit-
rate concentration was measured by coupling citrate
lyase and malate dehydrogenase according to Wil-
liamson and Corkey [18]. ATP contents were mea-
sured as previously reported [19]. All data were ex-
pressed per mg protein.
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2.3. Measurement of intracellular calcium ion and
cytosolic pH and NAD(P)H
Cells were plated on a glass-bottomed culture dish
and were incubated with HKRB bu¡er containing
5.5 mM glucose and 3 mM fura-2 AM (Molecular
Probes, Eugene, OR) for 30 min at room tempera-
ture and for 30 min at 37‡C. Cells were washed twice
with PBS(3) and examined by a £uorescence micro-
scope. Fura-2 £uorescence was measured using the
Argus 50/CA (Hamamatsu Photonics, Hamamatsu,
Japan), which allows £uorometry using two excita-
tion wavelengths (340 and 380 nm). Changes in intra-
cellular Ca2 ion ([Ca2]i) were expressed as the F340/
F380 ratio [19]. Auto£uorescence derived from
NAD(P)H was excited at 360 nm and measured at
470 nm as reported [19]. Cytosolic pH changes were
measured by incubating the cells with 5.5 mM glu-
cose and 3 mM 3P-O-acetyl-2P,7P-bis(carboxyleth-
yl)-4 or 5-carboxy£uorescein acetomethoxyl-ester
(BCECF-AM) (Molecular Probes) for 30 min at
room temperature and for 30 min at 37‡C. They
were washed twice with PBS(3) and examined by a
£uorescence microscope. BCECF £uorescence was
measured using two excitation wavelengths (450
and 470 nm) [20]. Data were expressed as the F470/
F450 ratio.
2.4. Analysis of pyruvate carboxylase
PC protein was analyzed using biotin-blotting
methods [21]. After MIN6 cells were incubated
with/without palmitate for 72 h, cells were washed
twice with ice cold PBS and harvested in PBS con-
taining 1 mM phenylmethylsulfonyl £uoride. Cells
were then disrupted by the sonication. Samples
equivalent to 20 g protein were resolved on 7.5%
SDS^polyacrylamide gels and electrotransferred to
nitrocellulose membranes. The membranes were in-
cubated for 2 h with streptavidin-biotinylated horse-
radish peroxidase complex. Biotin binding proteins
were revealed using enhanced chemiluminescence re-
agents (ECL system, Amersham Pharmacia Biotech,
Buckinghamshire, UK). Total cytoplasmic RNA was
isolated using the Trizol isolation method (Gibco
BRL, Rockville, MD). The amount of RNA was
estimated by spectrophotometry at 260 nm. Reverse
transcription^polymerase chain reaction (RT^PCR)
was performed in the ¢rst-strand cDNA from 10 g
of RNA and was electrophoresed in precast 5^10%
gradient acrylamide gel (Ready gel J 7.5%, Bio-Rad,
Hercules, CA) in TBE bu¡er. Gels were stained with
Cyber Green 1 (Molecular Probes), and analyzed by
using Fluoroimager 545 (Molecular Dynamics, Sun-
nyvale, CA). The synthetic oligonucleotide primer
sequences were 5P-GAGGCCTGGGCCTCGGGTG-
GAGCAG and 5P-TCGGCGGACACCCAGGAG-
CCTCAGG for PI transcript; 5P-CAGCGGCGGC-
CACGGCTAGAGGCG and 5P-TCGGCGACACC-
CAGGAGCCTCAGG for PII transcript taken from
the published sequence [22].
2.5. Measurement of lipid metabolism
After the pre-incubation for 3 days in DMEM
containing 5.5 mM glucose with/without palmitate,
lipids were extracted from the cells as reported [23]
and FFA and triglyceride were assayed enzymati-
cally. Brie£y, cells were scraped in 1 ml phosphate-
bu¡ered saline (PBS), pelleted by centrifugation, and
resuspended in 2.5 ml chloroform, 1.5 ml methanol
and 1.25 ml water. An aliquot of the chloroform
phase was dried and total triglyceride and FFA con-
centration were measured with NEFA-C test Wako
(Wako Chemical) and Lipidos Ace (Toyobo). Incor-
poration of [U-13C]glucose or [2-3H]glycerol into lip-
ids was measured as described [23]. Total lipid was
extracted from the cells with the Bligh^Dyer method.
L-Oxidation of acyl-CoA was measured as the pro-
duction of tritiated water from [9,10-3H]palmitic acid
as reported [24]. Malic enzyme activity was measured
as follows. 107 MIN6 cells were sonicated in 0.8 ml
50 mM triethanolamine hydrochloride/NaOH bu¡er
(pH 7.4) containing 3.0 mM MnCl2 and 0.02 mg/ml
BSA. This homogenate (50 Wl) was mixed with 500 Wl
of 0.4 M triethanolamine bu¡er, 0.2 ml of 3.4 mM
NADP, 0.05 ml of 0.03 M malate and 0.1 ml of
0.12 M MnCl2c4H2O. The NADPH formed was
monitored by spectrophotometry for 20 min incuba-
tion at 37‡C. Determination of intracellular NADPH
in MIN6 was measured as described [25] with a mi-
nor modi¢cation. To avoid the oxidation of the re-
duced pyridine nucleotides, samples were extracted
using NaOH and boiled at 65‡C for 10 min as re-
ported [26].
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2.6. Measurement of insulin secretion and contents
Insulin secretion was measured by a static incuba-
tion method using rat insulin as a standard. After 48
h of culture in DMEM (low glucose) with/without
BSA^palmitate complex, the medium was removed,
and cells were washed three times with PBS(3). Pal-
mitate was complexed to 1% BSA as previously de-
scribed [27]. Preincubation was performed for 80 min
in HKRB bu¡er. Cells were further incubated for 20
min in fresh HKRB bu¡er. They were then incubated
for 20 min in HKRB bu¡er with 0.5% BSA supple-
Fig. 1. Intracellular NAD(P)H, Ca2 and cytosolic pH changes to glucose in 1 mM palmitate-treated MIN6. Cells were incubated in
HKRB containing 3 mM fura-2 AM for 30 min at room temperature and 30 min at 37‡C. Then dishes were washed twice and incu-
bated in HKRB for 30 min at 0‡C. The response of fura-2 (A,B), BCECF £uorescence (C,D) to 25 mM glucose, and of NAD(P)H
auto£uorescence (E,F) to 10 mM glucose was measured. Thick and thin lines represent the responses obtained from the control
MIN6 and palmitate-treated MIN6, respectively.
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mented with various concentrations of glucose, and/
or stimulants. Insulin content was measured using
the supernatant of the sonicated extract.
Student’s t-test was used for statistical analysis
throughout the study.
3. Results
3.1. E¡ect of palmitate on glucose metabolism
In the palmitate-treated MIN6 cells, glucose phos-
phorylation and glucose utilization at 5.5 and 15 mM
glucose were unchanged as compared with the un-
treated MIN6 cells. Glycerol phosphate shuttle activ-
ity at 15 mM glucose was una¡ected by the FFA
treatment. Lactate production at 15 mM glucose
was about twice the control in the FFA-treated
MIN6 (Table 1). Citrate output at 15 mM glucose
was decreased in the presence of 0.25 and 1 mM
palmitate (Table 1). ATP contents at 5.5 mM and
15 mM glucose were increased in the presence of
both 0.25 and 1 mM palmitate (Table 1).
3.2. E¡ect of palmitate on [Ca2+]i, cytosolic pH and
NAD(P)H
During the glucose-stimulated insulin secretion,
[Ca2]i and cytosolic pH increased, changes in
[Ca2]i were unchanged in 0.25 mM palmitate
MIN6 cells, but attenuated in the 1 mM palmitate-
treated MIN6 (Fig. 1A,B). Intracellular pH incre-
ment after glucose stimulation was almost blunted
in palmitate-treated cells (Fig. 1C,D). Intracellular
NAD(P)H re£ects the mitochondria-bound NADH
content and parallels the intracellular ATP content
Fig. 2. The e¡ect of FFA on pyruvate carboxylase protein and
pyruvate carboxylase mRNA by the long-term exposure of pal-
mitate. Cells were incubated for 3 days with DMEM containing
5.5 mM glucose with and without 0.25, 0.5 and 1.0 mM palmi-
tate. PC protein was detected by using the biotin blotting meth-
od (A,B). Pyruvate carboxylase protein in the media containing
various concentrations of palmitate was measured (A). The ef-
fect of carnitine palmitoyl transferase I inhibitor and the re-
moval of palmitate (B) on PC protein was measured. Pyruvate
carboxylase mRNA expression by palmitate treatment was ana-
lyzed by the RT^PCR method (C). M, P1, P2 indicate marker,
PI gene transcript and PII gene transcript, respectively.
Table 1
E¡ect of palmitate on glucose and pyruvate metabolism
Palmitate concentration (mM) 0 (n = 6) 1 (n = 6)
Glucose concentration (mM) 5.5 15 5.5 15
Glucose phosphorylation (H2O mol/mg protein/h) 0.091 þ 0.003 0.36 þ 0.078 0.091 þ 0.004 0.32 þ 0.02
Glucose utilization (H2O mol/mg protein/h) 0.083 þ 0.003 0.24 þ 0.013 0.083 þ 0.004 0.24 þ 0.02
Glycerol phosphate shuttle activity (H2O nmol/mg protein/h) 0.62 þ 0.03 1.63 þ 0.11 0.510 þ 0.054 2.04 þ 0.18
Lactate production rate (g/mg protein/20 min) 0.72 þ 0.05 0.84 þ 0.05 0.95 þ 0.156 1.53 þ 0.14*
ATP content (nmol/mg protein) 0.8 þ 0.03 1.55 þ 0.06 1.34 þ 0.01 1.91 þ 0.091
Citrate output (nmol/mg protein/h) 8.50 þ 0.16 12.2 þ 1.57 8.63 þ 0.46 10.34 þ 0.55
Data are mean þ S.E., *P6 0.05 vs 0 mM palmitate.
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[28]. In the present study, glucose-stimulated changes
in NAD(P)H were apparently a¡ected by the palmi-
tate treatment (Fig. 1E). But basal NAD(P)H con-
centration was increased at 0.25 and 1 mM palmi-
tate. Change in NAD(P)H response to pyruvate in
glucose-free medium re£ects pyruvate oxidation. Py-
ruvate-stimulated change in NAD(P)H was de-
creased at 1.0 mM palmitate (Fig. 1F).
3.3. E¡ect of palmitate on pyruvate carboxylase
protein accumulation
PC protein accumulation was decreased corre-
sponding to the palmitate concentration (Fig. 2A).
After 3 days of incubation in the presence of 1 mM
palmitate, removal of palmitate from the medium
partially restored the PC protein amount in 24 h
(Fig. 2B). RT^PCR analysis indicated that the Class
II form of PC transcript was expressed in MIN6
cells, which was decreased by FFA treatment (Fig.
2C).
3.4. E¡ect of palmitate on lipid metabolism
In FFA-treated cells, intracellular TG and FFA
contents were about twice the control. De novo lipo-
genesis from glucose was decreased. Rate of L-oxida-
tion of palmitate in FFA-treated MIN6 cells was
higher than that in untreated cells. Reduced NADPH
content in the FFA-treated MIN6 was decreased.
Malic enzyme activity was not a¡ected (Table 2).
As compared with 0 mM palmitate, reduced GSH
content was unchanged at 0.25 mM, but was de-
creased at 1 mM palmitate (Table 2).
Fig. 3. Inhibition of glucose-stimulated insulin secretion by long-term exposure to palmitate. MIN6 cells were precultured in the media
containing the various concentrations of palmitate for 3 days (A). After preincubation in glucose-free HKRB for 80 min, cells were in-
cubated for 20 min with 5.5 mM and then with 15 mM glucose. The ordinate indicates the ratio of insulin secretion with 15 mM ver-
sus 5.5 mM glucose for each 20-min incubation period. The media were collected and insulin concentrations in the media were mea-
sured using the EIA method. Insulin content of MIN6 after 3 days of exposure to palmitate was measured by the sonication method
(B). Glucose-stimulated insulin secretion was expressed as the percent release of insulin secretion to insulin (C). Results are
mean þ S.E. of six experiments. *P6 0.05 compared with control MIN6.
Table 2
E¡ect of palmitate on lipid metabolism
Palmitate concentration (mM)
0 (n = 6) 1 (n = 6)
Intracellular triglyceride content (mol/mg protein) 1.80 þ 0.17 3.24 þ 0.29*
Intracellular free fatty acid content (nmol/mg protein) 6.40 þ 0.82 10.93 þ 0.75*
Beta oxidation of acyl CoA (H2O nmol/mg protein/h) 0.60 þ 0.04 1.30 þ 0.20*
Incorporation of glucose into lipid (nmol/mg protein/h) 1.50 þ 0.08 0.65 þ 0.10*
Reduced NADPH (ng NADPH/mg protein) 265.4 þ 20.9 185.0 þ 9.0*
Reduced GSH content (nmol/mg protein) 216.9 þ 45.9 126.2 þ 13.9*
Malic enzyme (nmol/mg protein/h) 24.9 þ 2.76 21.3 þ 2.12
Data are mean þ S.E., P6 0.05 vs 0 mM palmitate.
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3.5. E¡ect of palmitate on insulin responses and
insulin content
Exposure of palmitate for 3 days inhibited glucose-
stimulated insulin secretion at 0.5 and 1.0 mM pal-
mitate (Fig. 3A). Insulin content was reduced corre-
sponding to the increase in the concentrations of
palmitate and the decrease in BSA% (Fig. 3B).
When insulin secretion was expressed as unit/mg in-
sulin content, basal insulin secretion was increased at
any concentration of palmitate, but insulin response
to high glucose was decreased in the presence of 0.5
and 1.0 mM palmitate (Fig. 3C). Increments of in-
sulin secretion in response to 20 mM pyruvate were
1.80 þ 0.58 and 1.15 þ 0.20 in control MIN6 and
FFA treatment, respectively. Those to 40 mM KCl
were 3.52 þ 0.30 and 3.69 þ 0.30 in control and FFA-
treated MIN6, respectively. Data are means þ S.E. of
six determinations.
4. Discussion
In obese patients, FFA is speculated to play a role
in the development of diabetes. FFA increases glu-
cose output from the liver and decreases glucose
uptake in skeletal muscles [1]. In islets of animal
models of diabetes, FFA impaired the glucose-
stimulated insulin secretion in vivo and in vitro
[5,7]. However, the contribution of FFA on the glu-
cose metabolism of islet has not yet been fully elu-
cidated. In one report, long-term exposure of FFA
inhibited glucose oxidation and insulin secretory re-
sponse to glucose [7], while in the other, oleate in-
creased oxygen consumption and did not alter ATP
synthesis [29]. In the present results, lactate produc-
tion was increased and cytosolic pH increment,
which represents the increase in mitochondrial py-
ruvate £ux, was decreased in FFA-treated MIN6.
Glycolytic £ux was una¡ected by the exposure of
FFA (Table 1). Pyruvate carboxylase is abundantly
expressed in pancreatic L cells and facilitates
the supplementation of TCA-cycle intermediates
[12,30]. Pyruvate carboxylase was decreased at 0.5
and 1.0 mM palmitate (Fig. 2A). Glucose-induced
ATP synthesis and mitochondrial NAD(P)H accu-
mulation were increased by the FFA treatment. No-
tably, long-term FFA treatment markedly enhanced
L-oxidation and inhibited pyruvate oxidation (Table
2 and Fig. 1F).
Pyruvate is metabolized via two major pathways
of pyruvate dehydrogenase and pyruvate carboxylase
[12]. PC is abundantly expressed in L cells and sup-
plies oxaloacetate into the TCA cycle. PC gene tran-
scription is regulated by the two promoters, hor-
mone-sensitive PI and constitutive PII [22]. PC PII
mRNA is the dominant form expressed in islets [30].
In our results, PC PII but not PC PI mRNA was
detected in MIN6 and was decreased by the FFA
treatment (Fig. 2C). This suggests that PC gene
type II transcript contributes to the supplementation
of TCA-cycle intermediates (anaplerosis). Since re-
moval of palmitate from the medium restored PC
protein accumulation and glucose sensitivity in the
present study (Fig. 2B), FFA may have induced the
glucose insensitivity of the L cells as well as the in-
hibition of PC gene transcription.
A decrease in pyruvate oxidation is apparently in-
compatible with the unchanged ATP synthesis. Re-
cently, it is reported that the pyruvate mitochondrial
transporter inhibitor, K-cyano-4-hydroxycinnamate,
did not inhibit glucose-stimulated insulin secretion
[31]. ATP synthesis in pancreatic L cells is dependent
on both glycerol phosphate shuttle £ux and malate
aspartate shuttle £ux [32]. The inhibition of aconitase
does not inhibit ATP synthesis and glucose-stimu-
lated insulin secretion [32]. Since the glycerol phos-
phate shuttle activity was una¡ected either in 5.5 or
in 15 mM glucose (Table 1) and a decrease in pyru-
vate oxidation did not decrease ATP synthesis in
FFA treatment (Table 1), the present results indi-
cated that the inhibition of pyruvate oxidation is
not essential for the establishment of glucose insen-
sitivity and ATP synthesis. Insulin secretion in re-
sponse to glucose and pyruvate was decreased in
FFA-treated MIN6 cells, but that to KCl remained
intact. These suggest that the step distal to the volt-
age-dependent Ca2 channel is intact. Considering
that the ATP synthesis is intact after FFA treatment,
factors other than the ATP/ADP ratio including cy-
tosolic redox condition may be needed in fully estab-
lishing the glucose-stimulated insulin secretion pro-
cess.
Long-term treatment of FFA is reported to de-
crease insulin content possibly due to the insulino-
tropic e¡ect and inhibition of insulin biosynthesis
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[6,33]. In the present results, insulin content of FFA-
cultured MIN6 cells was decreased corresponding to
the concentrations of palmitate (Fig. 3C). Insulin
mRNA measured by RT^PCR methods in FFA-
treated MIN6 indicated that insulin mRNA was
not decreased (data not shown). The previous report
that decrease in insulin content was not due to the
decrease in insulin mRNA transcription [6,33] can be
compatible to this observation.
Reportedly, TG accumulation and de novo lipo-
genesis from glucose was increased and L-oxidation
was decreased in FFA-treated islets of Zucker dia-
betic fatty rats [21,34]. The expression of fatty acid
synthase in normal islets is very low and the physio-
logical signi¢cance of de novo lipogenesis in L cells
may be controversial. Recently, TG accumulation, L-
oxidation of acyl-CoA and expression of carnitine
palmitoyl transferase I mRNA were reported to be
increased by the exposure of FFA [34,35]. Inhibitors
of carnitine palmitoyl transferase I decreased the L-
oxidation rate and improved the glucose-stimulated
insulin secretion in the FFA-treated islets [7]. Like-
wise, in our results de novo lipogenesis from glucose
was small and FFA induced the inhibition of endog-
enous lipogenesis and increased L-oxidation (Table
2). An increase in TG accumulation and de novo
lipogenesis may not contribute largely to the inhibi-
tion of glucose-stimulated insulin secretion. Empha-
sis might be placed more on the enhanced L-oxida-
tion in the establishment of pancreatic L-cell
dysfunction [36].
NADPH is mainly supplied by the malate pyru-
vate shuttle in pancreatic L cells [9]. Another
NADPH-producing pathway, pentose phosphate
shuttle, is not active in pancreatic L cells [9]. Indeed,
glucose-6-phosphate dehydrogenase activity was not
a¡ected by FFA treatment (data not shown). The
malate pyruvate shuttle is composed of malic enzyme
and pyruvate carboxylase, and its £ux is regulated by
de novo lipogenesis which is regulated by pyruvate
carboxylase and acetyl CoA carboxylase. In palmi-
tate-treated MIN6 cells, NADPH content and citrate
output, which indicate pyruvate malate shuttle £ux,
were decreased (Tables 1 and 2). Malic enzyme ac-
tivity in FFA-treated MIN6 cells was not decreased,
and pyruvate carboxylase protein accumulation was
decreased. This indicated that a decrease in PC was
associated with the reduced cytosolic NADPH con-
tent. In our preliminary experiments, two di¡erent
inhibitors of malic enzyme, 2-bromo-pyruvate and
hydroxy-malonate, inhibited malic enzyme activity
and response of insulin and [Ca2]i to glucose (data
not shown). Recently Prentski et al. reported that
pyruvate carboxylase inhibitor inhibited glucose-
stimulated insulin secretion and pyruvate malate
shuttle £ux. It is also reported that a decrease in
cytosolic NADPH desensitized voltage-dependent
Ca2 channel and eventually inhibited glucose-stimu-
lated insulin secretion in islets [37]. As recently re-
ported, acyl-CoA caused a 40% reduction in cyto-
solic Ca2 concentration [38] and the KATP channel
is activated by long-chain acyl-CoA [39]. Ca2 re-
sponsiveness to high glucose in FFA-treated MIN6
was clearly decreased (Fig. 1A,B). Thus, it is sug-
gested that a decrease in NADPH and an increase
in cytosolic acyl-CoA inhibited the response of the
voltage-dependent Ca2 channel, resulting in the at-
tenuation of the glucose-stimulated insulin secretion.
We conclude that long-term exposure of pancreatic
L cells to FFA decreases pyruvate £ux into mito-
chondria and increased L-oxidation by decreasing
pyruvate carboxylase protein and the malate pyru-
vate shuttle £ux. Dysregulation in malate pyruvate
shuttle and PC gene expression would be a crucial
mechanism as the metabolic consequence of long-
term FFA treatment. The key factor for the FFA-
induced glucose insensitivity of the pancreatic L cells
was closely associated with the decreased cytosolic
NADPH content.
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